Takeda has entered into a multi-year strategic partnership with Iambic to utilize artificial intelligence in advancing small molecule drug programs. The total value of the deal is projected to potentially exceed $1.7 billion.
The collaboration will primarily leverage Iambic’s proprietary NeuralPLexer model, which specializes in predicting protein-ligand complex structures. Initial efforts will be directed toward high-priority projects in oncology, gastroenterology, and inflammatory therapeutic areas.
Under the agreement, Takeda will provide upfront payments, research funding, and technology access fees. Iambic is also eligible for milestone-based payments exceeding $1.7 billion, alongside royalties on net sales of any successful market entries.
Takeda’s leadership noted that integrating Iambic’s AI platform and automated wet lab capabilities aims to de-risk candidate selection and enhance the overall probability of success. This initiative is designed to accelerate the transition of selected programs from early-stage discovery to Investigational New Drug (IND) filings, reflecting Takeda’s broader ambition to harness cutting-edge science in delivering impactful new medicines.
Source: https://www.pharmaceutical-technology.com/news/takeda-iambic-small-molecule-programmes/?cf-view